21 Background 22 Laboratory diagnosis of Clostridium difficile infection (CDI) remains unsettled, despite updated 23 guidelines. We investigated the potential utility of quantitative data from a nucleic acid amplification 24 test (NAAT) for C. difficile toxin gene (tg) for patient management. 25 Methods 26 Using data from the largest ever C. difficile diagnostic study (8853 diarrhoeal samples from 7335 27 patients), we determined the predicative value of C. difficile tgNAAT (Cepheid Xpert C.diff) low cycle 28 threshold (CT) value for patient toxin positive status, CDI severity, mortality and CDI recurrence.
can occurs in up to 20% of inpatients [4] . There is a high prevalence of hospital onset diarrhoea 52 (HOD) from other causes [5] , and so without a direct toxin assay, a positive tgNAAT assay may simply 53 reflect the detection of "bystander" organism in a patient colonised by C. difficile. Over-diagnosis of 54 CDI in hospitals using standalone tgNAAT can lead to unnecessary treatment, overburden on limited 55 isolation facilities and may cause clinicians to overlook the real underlying diagnosis. 56 European guidelines recommend C. difficile tgNAAT should only be used as part of a two-stage 57 algorithm, with a toxin detection assay as the second stage [2] . Two-stage algorithms using a 58 glutamate dehydrogenase enzyme immunoassay (EIA) or a tgNAAT followed by toxin detection have 59 been widely adopted in the UK [6] . In 2013, 48% of hospitals in 20 European countries were using an 60 optimised algorithm for laboratory diagnosis of CDI, a relative increase of 50% from the previous 61
year [6] . In a univariate analysis, a CT ≤25 was significantly associated with a toxin positive result, presence of 118 PCR-ribotype 027, and mortality with a positive predictive value of 83.9% ) for toxin detection (Table   119 1 and Figure 3 ). However the sensitivity and specificity for CT≤25 to determine the presence of toxin 120 in tgNAAT positive samples were 51.3% (366/713,95%CI 48-55%) and 87.5% (491/561, 95%CI 84-121 90%) respectively.
122
A CT ≤24 was also significantly associated with a toxin positive result and the presence of PCR-123 ribotype 027, with a PPV of 86.1% for toxin detection (Table 1 and Figure 3 ). Due to the slight 124 advantage of using CT ≤25 over ≤24 as a cut-off, further analyses defined low CT as ≤25.
125
Patients with a low CT (≤25) had higher mean WCC, a higher baseline mean serum creatinine, lower 126 mean serum albumin and longer length of stay, but these differences were not significant (except 127 serum creatinine p = 0.04, Table 1 ). For patients with both a low CT and the presence of PCR-128 ribotype 027, mortality risk and LOS were significantly increased ( Table 1 ). The PPV of low CT for 129 mortality in this population was 17.4% (95% CI 13.5-22.2%); the negative predictive value (NPV) of 130 CT >25 for mortality was 88.0% (65% CI 85.0-90.5%). The relative risk of mortality in CDI with low CT 131 was 1.45 (95% CI 1.0-2.0, p = 0.04), which increased to 2.18 (95% CI 1.2-4.0p = 0.03) in cases also due 132 to PCR-ribotype 027.
133
The relative risk of mortality in CDI with low CT and a positive binary toxin gene test was 1.72 (95% 134 CI 1.1-2.8, p =0.05), with a significant difference in mortality rates between those with versus 135 without binary toxin gene (25.3 vs 14.7%, p = 0.049, Table 1 ). There was no difference in the rate of 136 toxin positive (CTA) samples between those with or without detection of the binary toxin gene 137 (Table 1) . Patients with a low CT and who were binary toxin positive had higher mean WCC, a higher 138 mean serum creatinine lower mean serum albumin and shorter LOS; of these differences, only 7 139 increased serum creatinine was significant (p = 0.006) (Table 1) This is the largest study to date examining the clinical utility of tgNAAT CT value to predict the 152 diagnosis and outcomes of CDI. Importantly, this is the only study that has tested all samples with 153 both the CTA and CTC reference assays. We have shown that a low tgNAAT CT value (≤25) is 154 significantly associated with a toxin positive status, presence of PCR-ribotype 027, and mortality.
155
Laboratory defined CDI recurrence was also associated with low CT, although this was not 156 significant, possibly due to the low number of such cases within the dataset. The median tgNAAT CT 157 value for patients who died was significantly lower than for those who survived (25.5 vs 27.5 p = 158 0.021) with a significant AUROCC for NAAT positives and mortality; 0.572 p =0.009. In addition, the 159 median tgNAAT CT value for a diarrhoeal sample that was (CTA) toxin positive was 24.9 compared 160 with 31.6 for toxin negative samples ( p <0.001); the AUROC here was 0.83 (p <0.001). difference between these (Table 1) ; a slighter higher PPV for toxin positivity using CT ≤24 was offset 163 by the lack of significant association with mortality seen using CT threshold ≤25. We therefore used 164 CT ≤25 as our 'low CT' threshold, which was slightly higher than found in two smaller recent studies 
